Entera Bio secures $10M to fund phase 3 osteoporosis drug trial
Entera Bio Ltd., a clinical-stage biopharmaceutical company, has secured a private placement deal to raise around $10.0 million. The funding will support a phase 3 trial for its lead drug candidate, EB613, an oral osteoporosis treatment. The agreement involves selling shares and warrants to investors, with the transaction expected to close by early April 2026. The company will issue 7,827,789 units, each priced at $1.2775. Every unit includes one ordinary share and a warrant to buy one and a half additional shares at $1.24 each. These warrants will be exercisable six months after the deal closes and remain valid for five years.
If all warrants are exercised, Entera could raise an extra $14.5 million. The funds will primarily finance the phase 3 study of EB613, a once-daily oral tablet designed to rebuild bone in osteoporosis patients. The company also plans to use the proceeds for general operations and working capital. EB613 is Entera's most advanced product, positioned as the first oral, bone-building treatment for osteoporosis. Currently, the firm has no other peptide-based therapies in development beyond this programme. The private placement remains subject to standard closing conditions, with completion targeted for April 2, 2026.
The financing will provide Entera with resources to advance its phase 3 trial for EB613. If fully exercised, the warrants could bring total proceeds to roughly $24.5 million. The company's focus remains on developing oral peptide therapies, with EB613 as its sole active clinical programme.
Read also:
- India's Agriculture Minister Reviews Sector Progress Amid Heavy Rains, Crop Areas Up
- Cyprus, Kuwait Strengthen Strategic Partnership with Upcoming Ministerial Meeting
- Inspired & Paddy Power Extend Virtual Sports Partnership for UK & Ireland Retail
- South West & South East England: Check & Object to Lorry Operator Licensing Now
